Understanding the 'Wearing Off' Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Natalizumab (Primary) ; Ocrelizumab (Primary) ; Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 May 2023 Status changed from recruiting to completed.
- 25 Apr 2023 Planned End Date changed from 15 Mar 2023 to 5 May 2023.
- 25 Apr 2023 Planned primary completion date changed from 15 Mar 2023 to 5 May 2023.